Pfizer’s presence at ASCO 2024
Positive results from ECHELON-3 Phase 3 study
Regimen produced clinically meaningful improvement in overall survival for certain patients with relapsed/refractory diffuse large b-cell lymphoma (DLBCL).
Find Out MoreNew 4-year data in advanced classical Hodgkin lymphoma
Takeda and Pfizer announce positive four-year results from Phase 3 HD21 trial of combination treatment regimen in frontline classical Hodgkin lymphoma.
Find Out MoreNew data from CROWN study
Five year follow-up data shows prolonged progression-free survival in ALK-positive advanced lung cancer.
Find Out MoreUnderstanding ALK-Positive Advanced Non-Small Cell Lung Cancer
Background information about a rare, aggressive form of lung cancer called ALK-positive non-small cell lung cancer.
Find Out MoreBreaking new ground with lung cancer research
Advances in scientific research have brought new hope for patients with a rare, aggressive form of lung cancer.
Find Out MoreHighlighting progress in accelerating breakthrough cancer medicines at ASCO
Pfizer is showcasing new research across the company’s key tumor areas and core scientific modalities, including small molecules, antibody-drug conjugates and bispecific antibodies.
Find Out MorePfizer-sponsored abstracts at ASCO
More than 50 abstracts will be presented from Pfizer’s broadened portfolio of approved and pipeline therapies.
See Our Abstract ListPfizer Abstract Plain Language Summaries (APLS)
To help non-scientists better understand the latest research, we are providing abstract plain language summaries for key data at ASCO.
Find Out MoreDriving cutting-edge science forward
Pfizer leaders share progress toward our vision: a world where people with cancer live better and longer lives.
Find Out MorePress Releases
All Pfizer published press releases by date and/or category of news
06.04.2018 Research Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations 06.04.2018 Medicines Research Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab) 05.23.2018 Research FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy 05.22.2018 Research A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+ 05.22.2018 Research Vaccines Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine 05.21.2018 Research Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events 05.17.2018 Medicines Research LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint 05.16.2018 Research Pfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCO 04.12.2018 Research Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy 04.10.2018 Research Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery 04.03.2018 Research Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio 03.29.2018 Research Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy
Trust in Technology – A Snapshot
Pfizer surveyed adults in 10 countries across the Global North and South to better understand the general population's trust in incorporating technology into the management of their healthcare. The results showed that 6 in 10 trust technology in this setting but that means 4 in 10 are at risk of being left behind. Our findings underscored that patients won’t feel the full benefits of that technology if we don’t have trusted people – specifically health care providers – delivering it. We must partner with patients, healthcare providers, policy makers and others in the life sciences and tech industries to build trust in the technologies that are fueling the future of health.
Downloadable InfographicDetails
![](https://cdn.pfizer.com/pfizercom/2024-01/Trust-in-technology-web.png?VersionId=2KG2ZtrRk3y.qirSYpPBLhhToMpIld5m)
Media Asset Library
A collection of assets for use by media.
Partnering News
The latest news from Pfizer and its strategic partners
12.16.2021 Partnerships Anaveon to raise CHF 110 million in oversubscribed Series B financing 11.29.2021 Partnerships Ranok Therapeutics Announces Agreement with Pfizer on Targeted Protein Degradation
Media Contacts
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
Media Contacts
General email
[email protected]
United States, Canada and Latin America
+1 212.733.1226
Europe, the Middle East and Africa
+44-(0)173.733.2335
[email protected]
Asia Pacific
+65.918.732.47
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Other Frequently Visited Links
For more, see these helpful and often used sections of Pfizer.com
Pfizer Wire
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.
Sign Up NowDetails
![](https://cdn.pfizer.com/pfizercom/2022-10/Pfizer_Brand-Motif_11%201%20%282%29.png?VersionId=JnyLe.ug92gda5lKzC5ji4yB3hAoYuia)